Antivirals: Difference between revisions

Revision as of 20:14, 19 September 2019

HIV regimen that typically consists of combination of 2 nucleoside and/or non-nucleoside reverse transcriptase inhibitors PLUS a protease inhibitor, reverse-transcriptase inhibitor, or integrase inhibitor
US DHHS first-line regimens
- Emtricitabine/tenofovir (Truvada) + raltegravir
- Emtricitabine/tenofovir + dolutegravir
- Abacavir/lamivudine (Epzicom) + dolutegravir OR abacavir/lamivudine/dolutegravir (Triumeq)
- Emtricitabine/tenofovir/elvitegravir/cobicistat (Stribild)
- Emtricitabine/tenofovir + ritonavir + darunavir
WHO first-line regimen
- Emtricitabine/tenofovir/efavirenz (Atripla)
- Tenofovir + lamivudine + efavirenz

Authors:

Revision as of 23:33, 17 June 2018 (view source) Jonwarren (talk \| contribs) (Updated links) ← Older edit		Revision as of 20:14, 19 September 2019 (view source) ClaireLewis (talk \| contribs) No edit summary Newer edit →
Line 42:		Line 42:
	<references/>		<references/>

	[[Category:Pharmacology]]		[[Category:Pharmacology]] [[Category:ID]]